Breast Cancer Research and Treatment

, Volume 27, Issue 1–2, pp 83–93 | Cite as

The role of erbB2 signal transduction pathways in human breast cancer

  • Ruth Lupu
  • Marc E. Lippman
William L. McGuire Memorial Symposium


The erbB2 receptor is expressed at very high levels in nearly 30% of human breast cancer patients and plays an important role in the transformation and the prognosis of breast cancer. While evidence accumulates to support the relationship between erbB2 overexpression and poor overall survival in human breast cancer, understanding of the biological consequence(s) of erbB2 overexpression remains elusive. Our recent discovery, cloning, sequencing, and expression of the erbB2 ligand (gp30) has allowed us to identify a number of related but distinct biological endpoints which appear responsive to signal transduction through the erbB2 receptor. These endpoints of growth, invasiveness, and differentiation have clear implications for the emergence, maintenance, and/or control of malignancy, and represent established endpoints in the assessment of malignant progression in breast cancer. Studiesin vitro have shown that gp30 induces a biphasic growth effect (induction of growth at low concentrations and inhibition of growth at high concentrations) on cells with erbB2 over-expression. Strikingly, we have recently observed that the erbB2 signalling pathway can be modulated by estrogen acting through the estrogen receptor (ER). Conversely, we observed that down regulation of erbB2 by estrogen can be blocked by gp30 acting through the erbB2 receptor. Clearly, mechanistic aspects of the erbB2/ligand interaction need to be understood from a therapeutic standpoint, and may furthermore provide additional insights into treatment synergy for particular patients. We think that these studies will facilitate the emergence of erbB2-targeted therapy.

Key words

erbB2 signal transduction erbB2 ligand estrogen receptor gp30 breast cancer progression 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henderson I, Harris J, Kinne D, Hellman S:In De Vita V, Hellman S (eds) Principles and Practice of Oncology. Lippincott, Philadelphia, 1989, pp 1197–1268Google Scholar
  2. 2.
    Schecter AL, Stern DF, Vaidyanathan L, Decker SJ: The neu oncogene: an erbB-related gene encoding a 185,000 Mr tumour antigen. Nature 312:513–516, 1984Google Scholar
  3. 3.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182, 1987Google Scholar
  4. 4.
    Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R:neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239–1245, 1988Google Scholar
  5. 5.
    Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H: ErbB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137–143, 1991Google Scholar
  6. 6.
    Nicholson S, Wright C, Sainsbury RC, Halcrow P, Kelly P, Angus B, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Molec Biol 37:811–814, 1990Google Scholar
  7. 7.
    Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeberg PhH, Libermann TA, Schlessinger J, Franke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with the neu oncogene. Science 230:1130–1139, 1985Google Scholar
  8. 8.
    Fukushige SI, Matsubaru K, Yoshida M: Localisation of a novel v-erbB-related gene, c-erbB-2, on chromosome-17 and its amplification in a gastric cell line. Mol Cell Biol 6:955–958, 1986Google Scholar
  9. 9.
    Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319:230–234, 1986Google Scholar
  10. 10.
    Schechter AL, Stern DF, Vaidyanathan L: An erbB related gene encoding a 185,000-Mr tumor antigen. Nature 312:513–516, 1984Google Scholar
  11. 11.
    Semba K, Kamata N, Toyoshima K, Yamamoto T: v-erbB related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497–6501, 1985Google Scholar
  12. 12.
    Muller W, Sinn E, Patengale P, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115, 1988Google Scholar
  13. 13.
    Bouchard L, Lamarre L, Tremblay P, Jolicoeur P: Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57: 931–936, 1989Google Scholar
  14. 14.
    DiFiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–182, 1986Google Scholar
  15. 15.
    Huziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p 185 (HER2) causes transformation and tumorigenesis of NIH3T3 cells. Proc Natl Acad Sci USA 84:7159–7163, 1987Google Scholar
  16. 16.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182, 1987Google Scholar
  17. 17.
    Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer. Association with comedotype ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239–1245, 1988Google Scholar
  18. 18.
    Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathological findings from National Surgical Adjuvant Breast Project (protocol B-06): prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103–112, 1990Google Scholar
  19. 19.
    Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087–2090, 1989Google Scholar
  20. 20.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712, 1988Google Scholar
  21. 21.
    Shih C, Padhy L, Murray M, Weinberg RA: Transforming genes of carcinoma and neuroblastomas introduced into mouse fibroblasts. Nature 290:261–264, 1981Google Scholar
  22. 22.
    Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptorrelated protein. Nature 319:226–230, 1986Google Scholar
  23. 23.
    Segatto O, King CR, Pierce JH, Di Diore PP, Aaronson SA: Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 5570-5574, 1988Google Scholar
  24. 24.
    Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK: A monoclonal antibody against c-erbB2 protein enhances the cytotoxicity of cis-diammine dichoroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575–4580, 1991Google Scholar
  25. 25.
    Wiltschke C, Tyl E, Steininger A, Zielinski C, Spona J, Zeilinger R, Kury F, Czerwenka K, Kubista E, Speiser P, Preis P: Increased NK-cell activity correlates with low or negative expression of the HER-2/neu oncogene in breast cancer patients. Proc AACR 32:203–203, 1991Google Scholar
  26. 26.
    Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H, Cline MJ: Amplification of c-erbB oncogene in human adenocarcinoma in vivo. Lancet i:765–767, 1986Google Scholar
  27. 27.
    Hudziak R, Lewis G, Winget M, Fendly B, Shepard H, Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165–1172, 1989Google Scholar
  28. 28.
    Drebin J, Link V, Stern D, Weinberg R, Greene M: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695–706, 1985Google Scholar
  29. 29.
    Lupu R, Colomer R, Zugmaier G, Shepard M, Slamon D, Lippman ME: Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science 249:1552–1555, 1990Google Scholar
  30. 30.
    Lupu R, Colomer R, Kannan B, Lippman ME: Characterization of a growth factor that binds exclusively to the erbB2 receptor and induces cellular responses. Proc Natl Acad Sci 89:2287–2291, 1992Google Scholar
  31. 31.
    Wahl MI, Daniel TO, Carpenter G: Antiphosphotyrosine recovery of phospholipase C activity after EGF treatment of A-431 cells. Science 241:968–970, 1988Google Scholar
  32. 32.
    Morrison DK, Kaplan DR, Escobedo JA, Rapp UR, Roberts TM, Williams LT: Direct activation of the serine/threonine kinase activity of raf-1 through tyrosine phosphorylation by the PDGF beta-receptor. Cell 58: 649–657, 1989Google Scholar
  33. 33.
    Molloy CJ, Bottaro DP, Fleming TP, Marshall MS, Aaronson SA: PDGF induction of tyrosine phosphorylation of GTPase activating protein. Laboratory of Cellular and Molecular Biology, National Cancer Institute. Nature 342:711–714, 1989Google Scholar
  34. 34.
    McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Research 51:3296–3303, 1991Google Scholar
  35. 35.
    Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947–3951, 1990Google Scholar
  36. 36.
    Lupu R, Perez C, Cho C, Lippman ME: Cloning of a family of ligands for the erbB-2 Receptor. (In preparation), 1993.Google Scholar
  37. 37.
    Huang SS, Huang JS: Purification and characterization of theneu/erb B2 ligand-growth factor from bovine kidney. J Biol Chem 267:11508–11512, 1992Google Scholar
  38. 38.
    Wen D, Peles E, Cupples R, Suggs SV, Bacus S, Lou Y, Trail G, Hu S, Silbiger SM, Ben Levi R, Koski R, Lu HS, Yarden Y:neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69:559–572, 1992Google Scholar
  39. 39.
    Holmes W, Sliwkowski MX, Akita RW, Henzel W, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis G, Shepard MH, Kuang WJ, Wood WI, Goeddel DV, Vandlen RL: Identification of heregulin, a specific activator of p185erbB2. Science 256:1205–1210, 1992Google Scholar
  40. 40.
    Lupu R, Wellstein A, Sheridan J, Ennis BW, Zugmaier G, Katz D, Lippman ME, Dickson RB: A novel biologically active polypeptide structurally and functionally related to TGFα: Purification and characterization. Biochem (in press), 1993.Google Scholar
  41. 41.
    Frackelton AR Jr, Tremble PM, Williams LT: Evidence for the platelet-derived growth factor-stimulated tyrosine phosphorylation of the platelet-derived growth factor receptor in vivo. J Biol Chem 259:7909–7915, 1991Google Scholar
  42. 42.
    Beitz JG, Kim IS, Calabresi P, Frackelton R Jr: Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc Natl Acad Sci USA 88:2021–2025, 1991Google Scholar
  43. 43.
    Cooper JA, Sefton B, Hunter T: Detection and quantification of phosphotyrosine in proteins. Meth Enzymol 99:387–402, 1983Google Scholar
  44. 44.
    Frackelton AR Jr, Ross AN, Eisen HN: Characterization and use of monoclonal antibodies for isolation of phosphotyrosyl proteins from retrovirus-transformed cells and growth factor-stimulated cells. Mol Cell Biol 3:1343–1352, 1983Google Scholar
  45. 45.
    Bacus S, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman ME, Lupu R: A ligand for the erbB2 oncogene product gp30 induces differentiation of human breast cancer cells. Cell Growth and Differentiation 3:401–411, 1992Google Scholar
  46. 46.
    Thompson E, Torri J, Arand G, Lippman ME, Lupu R: The GP30 ligand for the erbB2 receptor stimulates human breast cancer cell migration and chemoinvasion [abstract]. Proc AACR 33:66, 1992Google Scholar
  47. 47.
    Westley B, Rochefort H: A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20:353–362, 1988Google Scholar
  48. 48.
    Bronzert DA, Silverman S, Lippman ME: Induction of a secreted protein in human breast cancer cells [abstract]. Proc 67th Ann Endo Soc Meet 26:252, 1985Google Scholar
  49. 49.
    Burke RE, Harris SC, McGuire WC: Lactate dehydrogenase in estrogen responsive human breast cancer cells. Cancer Res 38:2773–2780, 1978Google Scholar
  50. 50.
    Colomer R, Saceda M, Martin BM, Lippman ME, Lupu R: Cross-regulation rebB2 oncoprotein and estrogen receptor by estrogen and the erbB2 ligands (gp30/p75). Proc AACR 33, Abs 494, 1992Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Ruth Lupu
    • 1
  • Marc E. Lippman
    • 1
  1. 1.Vincent T. Lombardi Cancer Research CenterGeorgetown UniversityWashington DCUSA

Personalised recommendations